Investor Relations

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel medicines for the management of central nervous system (CNS) disorders. By focusing on this therapeutic area, we are addressing significant and growing markets where current treatment options are limited or inadequate. Our pipeline includes two late-stage product candidates, AXS-02 and AXS-05, which we are developing for multiple indications.

NASDAQ AXSM (Common Stock) $5.55 - 0.05 (0.89%)
Stock chart for: AXSM.O.  Currently trading at $5.55 with a 52 week high of $9.11 and a 52 week low of $3.53.
Data provided by Nasdaq. Minimum 15 minutes delayed.

Axsome Therapeutics to Present at Upcoming Investor Conferences

September 18, 2017NEW YORK, Sept. 18, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present a corporate overview at the following investor conferences: The Ladenburg Thalmann 2017 Healthcare Conference in New York, NY on Tuesday, September 26, 2017 at 9:30 AM Eastern Time. ... 

Axsome Announces CREATE-1 Interim Analysis Expected Year-End 2017

September 7, 2017Interim analysis results for both CREATE-1 and COAST-1 trials anticipated late December to early January NEW YORK, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that the interim efficacy analysis of the Phase 3 CREATE-1 trial of AXS-02 in complex regional pain syndrome (CRPS) is expected year-end 2017. The interim ana... 

Axsome Therapeutics Reports Second Quarter 2017 Financial Results

August 9, 2017NEW YORK, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the quarter ended June 30, 2017. “We continued our forward momentum in the second quarter with the expansion of our clinical programs as well as our team,” said Herriot Tabuteau, M.D., Chief Executive Officer of Axsome. “Our clinical pipelin...